188 related articles for article (PubMed ID: 31552220)
1. Structural, Thermodynamic, and Kinetic Traits of Antiestrogen-Compounds Selectively Targeting the Y537S Mutant Estrogen Receptor α Transcriptional Activity in Breast Cancer Cell Lines.
Pavlin M; Gelsomino L; Barone I; Spinello A; Catalano S; Andò S; Magistrato A
Front Chem; 2019; 7():602. PubMed ID: 31552220
[TBL] [Abstract][Full Text] [Related]
2. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
3. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers.
Pavlin M; Spinello A; Pennati M; Zaffaroni N; Gobbi S; Bisi A; Colombo G; Magistrato A
Sci Rep; 2018 Jan; 8(1):649. PubMed ID: 29330437
[TBL] [Abstract][Full Text] [Related]
4. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
5. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
6. Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer Cells.
Young KS; Hancock GR; Fink EC; Zigrossi A; Flowers B; Cooper DA; Ngyuen VT; Martinez M; Mon KS; Bosland MC; Zak D; Runde AP; Sharifi MN; Kastrati I; Minh D; Kregel S; Fanning SW
bioRxiv; 2024 Jun; ():. PubMed ID: 38854123
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Fanning SW; Mayne CG; Dharmarajan V; Carlson KE; Martin TA; Novick SJ; Toy W; Green B; Panchamukhi S; Katzenellenbogen BS; Tajkhorshid E; Griffin PR; Shen Y; Chandarlapaty S; Katzenellenbogen JA; Greene GL
Elife; 2016 Feb; 5():. PubMed ID: 26836308
[TBL] [Abstract][Full Text] [Related]
8. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Fanning SW; Jeselsohn R; Dharmarajan V; Mayne CG; Karimi M; Buchwalter G; Houtman R; Toy W; Fowler CE; Han R; Lainé M; Carlson KE; Martin TA; Nowak J; Nwachukwu JC; Hosfield DJ; Chandarlapaty S; Tajkhorshid E; Nettles KW; Griffin PR; Shen Y; Katzenellenbogen JA; Brown M; Greene GL
Elife; 2018 Nov; 7():. PubMed ID: 30489256
[TBL] [Abstract][Full Text] [Related]
9. Short chain fatty acids exhibit selective estrogen receptor downregulator (SERD) activity in breast cancer.
Schoeller A; Karki K; Jayaraman A; Chapkin RS; Safe S
Am J Cancer Res; 2022; 12(7):3422-3436. PubMed ID: 35968335
[TBL] [Abstract][Full Text] [Related]
10. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
11. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
Laws MJ; Ziegler Y; Shahoei SH; Dey P; Kim SH; Yasuda M; Park BH; Nettles KW; Katzenellenbogen JA; Nelson ER; Katzenellenbogen BS
Breast Cancer Res Treat; 2020 Jun; 181(2):297-307. PubMed ID: 32277377
[TBL] [Abstract][Full Text] [Related]
12. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract][Full Text] [Related]
13. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Caciolla J; Martini S; Spinello A; Pavlin M; Turrini E; Simonelli F; Belluti F; Rampa A; Bisi A; Fimognari C; Zaffaroni N; Gobbi S; Magistrato A
Eur J Med Chem; 2021 Nov; 224():113733. PubMed ID: 34364162
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines.
Gelsomino L; Panza S; Giordano C; Barone I; Gu G; Spina E; Catalano S; Fuqua S; Andò S
Cancer Lett; 2018 Aug; 428():12-20. PubMed ID: 29702197
[TBL] [Abstract][Full Text] [Related]
15. Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.
Chigira T; Nagatoishi S; Tsumoto K
Biochem Biophys Res Commun; 2015 Aug; 463(4):726-31. PubMed ID: 26049107
[TBL] [Abstract][Full Text] [Related]
16. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
17. Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.
Zhao Y; Laws MJ; Guillen VS; Ziegler Y; Min J; Sharma A; Kim SH; Chu D; Park BH; Oesterreich S; Mao C; Shapiro DJ; Nettles KW; Katzenellenbogen JA; Katzenellenbogen BS
Cancer Res; 2017 Oct; 77(20):5602-5613. PubMed ID: 28904064
[TBL] [Abstract][Full Text] [Related]
18. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
Huggins RJ; Greene GL
NPJ Breast Cancer; 2023 Nov; 9(1):96. PubMed ID: 38036546
[TBL] [Abstract][Full Text] [Related]
19. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
[TBL] [Abstract][Full Text] [Related]
20. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
